Results
eNauka >
Results >
HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2-overexpressing metastatic or advanced gastric/GEJ adenocarcinoma- Overall survival analysis.
| Title: | HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2-overexpressing metastatic or advanced gastric/GEJ adenocarcinoma- Overall survival analysis. | Authors: | Maglakelidze, Marina; ...; (broj, koautora 16) | Issue Date: | 2023 | Publication: | JOURNAL OF CLINICAL ONCOLOGY | ISSN: | 0732-183X Journal of Clinical Oncology Search Idenfier |
Type: | Conference Paper | Collation: | vol. 41 str. 289-289 | WoS-ID: | 001093994600366 | URI: | https://enauka.gov.rs/handle/123456789/866094 | Project: | Imugene Limited | Metadata source: | (Preuzeto iz Nasi u WoS) | M-category: | Mp. category will be shown later |
6
WEB OF SCIENCETM
Google ScholarTM
Items in eNauka are protected by copyright, with all rights reserved, unless otherwise indicated.